Stock Events

Stock Events

Sonnet BioTherapeutics 

€5.5
0
+€0+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
44
52W Low
44
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow H3D.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap739.55M
Allogene Therapeutics works on allogeneic CAR T therapies for cancer, directly competing with Sonnet's approach to cancer treatment.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is involved in gene editing for cancer therapies, competing in the innovative treatment space like Sonnet.
Fate Therapeutics
FATE
Mkt Cap177.91M
Fate Therapeutics focuses on programmed cellular immunotherapies for cancer patients, aligning closely with Sonnet's mission.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space for oncology, similar to Sonnet's focus.
Novartis
NVS
Mkt Cap279.67B
Novartis AG, with its CAR T-cell therapy Kymriah, competes in the advanced cancer treatment market alongside Sonnet.

About

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Show more...
CEO
Mr. Raghu Rao
Employees
13
Country
United States
ISIN
US83548R4020

Listings

STU
DE
H3D.STU

0 Comments

Share your thoughts

FAQ

What is Sonnet BioTherapeutics stock price today?▼
The current price of H3D.STU is €5.5 EUR — it has increased by +0% in the past 24 hours. Watch Sonnet BioTherapeutics stock price performance more closely on the chart.
What is Sonnet BioTherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sonnet BioTherapeutics stocks are traded under the ticker H3D.STU.
Is Sonnet BioTherapeutics stock price growing?▼
H3D.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Sonnet BioTherapeutics has showed a +0% increase.
How many employees does Sonnet BioTherapeutics have?▼
As of May 07, 2026, the company has 13 employees.
In which sector is Sonnet BioTherapeutics located?▼
Sonnet BioTherapeutics operates in the Health & Wellness sector.
When did Sonnet BioTherapeutics complete a stock split?▼
Sonnet BioTherapeutics has not had any recent stock splits.
Where is Sonnet BioTherapeutics headquartered?▼
Sonnet BioTherapeutics is headquartered in Princeton, United States.